- Tenoxicam
-
- $0.00 / 1g
-
2026-04-24
- CAS:59804-37-4
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 50kg/Month
- Tenoxicam
-
- $0.00 / 1KG
-
2026-04-24
- CAS:59804-37-4
- Min. Order: 1KG
- Purity: 98%min
- Supply Ability: 30tons/month
- Tenoxicam
-
- $0.00 / 1kg
-
2026-04-23
- CAS:59804-37-4
- Min. Order: 1kg
- Purity: 0.99
- Supply Ability: 1000kg
|
| | Tenoxicam Basic information |
| Product Name: | Tenoxicam | | Synonyms: | 4-Hydroxy-2-methyl-N-pyridin-2-yl-2H-thieno[2,3-e][1,2]thiazine-3-carboxamide 1,1-dioxide (Tenoxicam);MOBIFLEX;tilcotil;3-Chlorosulfonyl-2-thiophene carboxylic acid methy;Do1men;4-Hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2，3-e]-1，2-thiazine-3-carboxamidel，1-dioxide;2H-Thieno(2,3-e)-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide;4-Hydroxy-2-methyl-N-2-pyrimidinyl-2H-thieno[2,3-e]-1,2-thiazine-3-carboxamide 1,1-dioxide | | CAS: | 59804-37-4 | | MF: | C13H11N3O4S2 | | MW: | 337.37 | | EINECS: | 620-500-8 | | Product Categories: | Active Pharmaceutical Ingredients;Lipid signaling;Amines;Heterocycles;Sulfur & Selenium Compounds;Pharmaceutical raw material;Tenoxicam;Intermediates & Fine Chemicals;Pharmaceuticals;Fused Ring Systems;API;TARACTAN | | Mol File: | 59804-37-4.mol |  |
| | Tenoxicam Chemical Properties |
| Melting point | 209-2130C (dec) | | density | 1.4737 (rough estimate) | | refractive index | 1.6390 (estimate) | | storage temp. | 2-8°C | | solubility | Practically insoluble in water, sparingly soluble in methylene chloride, very slightly soluble in anhydrous ethanol. It dissolves in solutions of acids and alkalis. | | pka | pKa1 5.3, pKa2 1.1(at 25℃) | | form | Solid | | color | White to Yellow to Green | | Water Solubility | 61.9mg/L(32 ºC) | | Major Application | pharmaceutical
pharmaceutical small molecule | | InChI | InChI=1S/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18) | | InChIKey | LZNWYQJJBLGYLT-UHFFFAOYSA-N | | SMILES | S1(=O)(=O)C2C=CSC=2C(O)=C(C(NC2=NC=CC=C2)=O)N1C | | CAS DataBase Reference | 59804-37-4 |
| Hazard Codes | T,Xi | | Risk Statements | 23/24/25-36/37/38 | | Safety Statements | 36/37/39-45-36-26-36/37 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 2 | | RTECS | XJ9095060 | | HS Code | 2934.99.3000 | | HazardClass | 6.1 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Dermal
Acute Tox. 3 Inhalation
Acute Tox. 3 Oral |
| | Tenoxicam Usage And Synthesis |
| Description | Tenoxicam is a non-steroidal antiinflammatory agent with a profile similar to related
piroxicam and now withdrawn isoxicam (55). It is useful in the treatment of rheumatoid
arthritis, osteoarthritis and related disorders. | | Chemical Properties | Yellow Crystalline Powder | | Originator | Hoffmann-La Roche (Switzerland) | | Uses | Tenoxicam has been used:
as a non-steroidal anti-inflammatory agent (NSAID) to study its effects on root gravitropism in Arabidopsis thaliana
as a standard in microanalysis of NSAIDs by spectrophotometry
to test its effect on surface potential andmembrane fluidity modification in phosphoglyceride monolayers | | Definition | ChEBI: Tenoxicam is a thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic, an antipyretic and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a heteroaryl hydroxy compound, a monocarboxylic acid amide, a member of pyridines and a thienothiazine. | | Brand name | Tilcotil | | Biochem/physiol Actions | Tenoxicam (TX) possesses antipyreticand analgesic effects. It elicits radical scavenging activity and has the potential to treat enkylosing spondylitis, extra-articular diseases, acute gout, and rheumatic diseases. It is also effective in treating primary dysmenorrhea, postpartum uterine contraction pain, and post-operation backaches. TX is capable of inhibiting prostaglandin synthesis. | | Clinical Use | NSAID and analgesic | | Synthesis | The reaction of methyl 3-hydroxythiophene-
2-carboxylate with PCl5 in refluxing
CCl4 gives 3-chlorothiophene-2-carboxylic
acid, which by treatment with NaHSO3
and Cu in aqueous alkaline solution at 143 C
in a pressure vessel is converted into 3-
sulfothiophene-2-carboxylic acid. Its esterification
with refluxing methanol affords methyl-
3-sulfothiophene-2-carboxylate, which by reaction
with refluxing SOCl2 yields methyl-
3-chlorosulfonylthiophene-2-carboxylate. The
following condensation with sarcosine ethyl
ester in hot CHCl3 gives 3-(N-ethoxycarbonylmethyl-
N-methylsulfamoyl)thiophene-2-carboxylate,
which is cyclized by treatment with
sodium methoxide in refluxing methanol affording
3-ethoxycarbonyl-4-hydroxy-2-methyl-2Hthieno--1,2-thiazine 1,1-dioxide. Finally
this compound is condensed with 2-aminopyridine
in refluxing toluene | | Drug interactions | Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas
enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity. | | Metabolism | Metabolised in the liver via cytochrome P450 2C9 to
several pharmacologically inactive metabolites (mainly
5'-hydroxy-tenoxicam).
Metabolites are excreted mainly in the urine; there is
some biliary excretion of glucuronide conjugates of the
metabolites. | | References | [1] Patent: CN106916169, 2017, A. Location in patent: Paragraph 0026; 0027; 0028; 0029 |
| | Tenoxicam Preparation Products And Raw materials |
| Raw materials | Sulfuryl chloride-->2-Aminopyridine-->Methyl 3-hydroxythiophene-2-carboxylate-->Sarcosine-->3-CHLOROTHIOPHENE-->Ethyl 3-aminopropanoate hydrochloride-->2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-N-2-pyridinyl-, 1,1-dioxide-->METHYL 4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE-->METHYL 2-METHYL-4-HYDROXY-2H-THIENO[2,3-E]-1,2-THIAZINE-3-CARBOXYLATE-1,1-DIOXIDE-->Dimethyl carbonate |
|